Leerink Partnrs Forecasts Zai Lab FY2026 Earnings

Zai Lab Limited (NASDAQ:ZLAB) – Research analysts at Leerink Partnrs issued their FY2026 earnings per share estimates for shares of Zai Lab in a report issued on Thursday, February 27th. Leerink Partnrs analyst J. Chang forecasts that the company will earn $0.18 per share for the year. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share.

Other equities analysts also recently issued reports about the company. Cantor Fitzgerald raised Zai Lab to a “strong-buy” rating in a research report on Wednesday, February 5th. Bank of America reissued a “neutral” rating and issued a $36.10 price objective (up from $29.00) on shares of Zai Lab in a report on Monday.

Zai Lab Stock Down 8.4 %

ZLAB opened at $31.73 on Monday. The firm’s 50-day moving average price is $27.67 and its 200-day moving average price is $25.96. The company has a market cap of $3.47 billion, a P/E ratio of -11.45 and a beta of 1.02. Zai Lab has a 52-week low of $13.48 and a 52-week high of $36.60.

Zai Lab (NASDAQ:ZLAB) last announced its earnings results on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.19). The business had revenue of $109.07 million for the quarter, compared to analyst estimates of $110.15 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%.

Hedge Funds Weigh In On Zai Lab

Several institutional investors and hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in Zai Lab during the fourth quarter worth about $29,000. Pictet Asset Management Holding SA purchased a new position in shares of Zai Lab during the 4th quarter valued at approximately $31,000. Barclays PLC boosted its holdings in Zai Lab by 337.6% during the fourth quarter. Barclays PLC now owns 3,702 shares of the company’s stock worth $97,000 after buying an additional 2,856 shares in the last quarter. US Bancorp DE grew its position in Zai Lab by 1,671.9% during the fourth quarter. US Bancorp DE now owns 5,865 shares of the company’s stock valued at $154,000 after buying an additional 5,534 shares during the period. Finally, Jasper Ridge Partners L.P. purchased a new position in Zai Lab in the fourth quarter valued at $210,000. Institutional investors and hedge funds own 41.65% of the company’s stock.

Insider Transactions at Zai Lab

In other Zai Lab news, insider Rafael Amado sold 7,583 shares of the company’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $26.28, for a total value of $199,281.24. Following the sale, the insider now directly owns 33,834 shares of the company’s stock, valued at approximately $889,157.52. This represents a 18.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 13.88% of the company’s stock.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.